Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
- Diem S Departments of *Oncology ‡Ophthalmology #Dermatology/Allergology **Institute of Immunobiology, Kantonal Hospital St Gallen, St Gallen †Department of Oncology, Hospital Grabs, Grabs §Ludwig Cancer Research Center, University of Lausanne, Lausanne ∥Department of Dermatology ¶Private Ophthalmic Practice in Cooperation with the Skin Cancer Unit, University Hospital of Zurich, Zurich, Switzerland.
- Keller F
- Rüesch R
- Maillard SA
- Speiser DE
- Dummer R
- Siano M
- Urner-Bloch U
- Goldinger SM
- Flatz L
- 2016-09-24
Published in:
- Journal of immunotherapy (Hagerstown, Md. : 1997). - 2016
Aged
Antibodies, Monoclonal, Humanized
Autoimmunity
CTLA-4 Antigen
Humans
Immunotherapy
Ipilimumab
Male
Melanoma
Middle Aged
Neoplasms, Unknown Primary
Programmed Cell Death 1 Receptor
Skin Neoplasms
Treatment Outcome
Uveitis
English
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1097/CJI.0000000000000143
- PMID 27662340
- Persistent URL
- https://sonar.ch/global/documents/298513
Statistics
Document views: 34
File downloads:
- Full-text: 0